Search

Staphylococcus aureus is the third most dreaded pathogen posing a severe threat due to its refractory behavior against the current armamentarium of antimicrobial drugs. This is attributed to the evolution of an array of resistance mechanisms responsible for morbidity and mortality globally. Local and international travel has resulted in the movement of drug resistant S. aureus clones from hospitals into communities and further into different geographical areas where they have been responsible for epidemic outbreaks. Thus, there is a dire necessity to refrain further cross movement of these multidrug resistant clones across the globe. The plausible alternative to prevent this situation is by thorough implementation of regulatory aspects of sanitation, formulary usage and development of new therapeutic interventions. Various strategies like exploring novel antibacterial targets, high throughput screening of microbes, combinatorial and synthetic chemistry, combinatorial biosynthesis and vaccine development are being extensively sought to overcome multidrug resistant chronic Staphylococcal infections. The majority of the antibacterial drugs are of microbial origin and are prone to being resisted. Anti-staphylococcal plant natural products that may provide a new alternative to overcome the refractory S.aureus under clinical settings have grossly been unnoticed. The present communication highlights the new chemical entities and therapeutic modalities that are entering the pharmaceutical market or are in the late stages of clinical evaluation to overcome multidrug resistant Staphylococcal infections. The review also explores the possibility of immunity and enzyme-based interventions as new therapeutic modalities and highlights the regulatory concerns on the prescription, usage and formulary development in the developed and developing world to keep the new chemical entities and therapeutic modalities viable to overcome antimicrobial resistance in S. aureus. [ABSTRACT FROM AUTHOR]

The last decade witnessed the emergence of Staphylococcus aureus- a versatile human pathogen, as a deadly superbug. The enormous genetic plasticity of the organism assists it to endlessly evolve resistance mechanisms against existing anti-infectives thus necessitating the need to control the spread of resistant staphylococcal isolates in hospitals and health care settings. This in turn demands the incessant exploration of newer biological matrices in search of diverse chemical entities with novel drug targets. Since time immemorial higher plants continue to be the best source of newer compounds with high therapeutic potential. Lead fractions from same or different plants can be developed into effective antibacterial polyherbal formulations. A lead fraction from methanolic extract of leaves of Callistemon rigidus exhibited a dose dependent antistaphylococcal activity during in vitro agar well assay against a panel of twenty seven clinical multidrug resistant S. aureus isolates. Further, minimal inhibitory concentration (MIC) evaluation by in vitro 96-well microplate based assay established a MIC range of 1.25–80 μg/ml as compared to 5–320 μg/ml of positive control, Cefuroxime sodium. The MIC50 and MIC90 of the methanolic lead fraction were 5 μg/ml and 40 μg/ml respectively. The present study thus signifies the vast potential of the lead fraction from Callistemon rigidus for future development into a herbal drug/ formulation and to impede global health crisis due to multidrug resistant Staphylococcus aureus. [ABSTRACT FROM AUTHOR]

In vitro investigation of the antimicrobial activity of a crude methanol extract of leaves of Callistemon rigidus R.Br. (Myrtaceae) revealed potential antibacterial activity against a broad spectrum of multidrug-resistant human pathogens. Agar well diffusion assays of the test extract established significant concentration-dependent antibacterial activity against methicillin-resistant Staphylococcus aureus , vancomycin-intermediate Staphylococcus aureus , vancomycin-resistant Escherichia coli , extended spectrum β-lactamase-producing E. coli , and multidrug-resistant Pseudomonas spp. [ABSTRACT FROM AUTHOR]